We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 195

Court dismisses NOC proceeding for mootness when NOA withdrawn
  • Borden Ladner Gervais LLP
  • Canada
  • January 30 2013

Lilly brought an application for prohibition pursuant to the Patented Medicines (Notice of Compliance) Regulations. Subsequently, Teva established to


Court bifurcates determination of Start Date for section 8 action
  • Borden Ladner Gervais LLP
  • Canada
  • May 30 2014

This is an action commenced pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations. Pfizer counterclaimed against Apotex


Court of Appeal upholds decision awarding Section 8 compensation where sales related to “unauthorized indications” Sanofi-Aventis Canada Inc. v. Teva Canada limited, 2014 FCA 69
  • Borden Ladner Gervais LLP
  • Canada
  • March 24 2014

Drug: ramipril This was an appeal by Sanofi-Aventis Canada Inc. and Sanofi-Aventis Deutschland GmbH (collectively "Sanofi") from a judgment of the


Teva's allegation for section 8 damages not struck on appeal
  • Borden Ladner Gervais LLP
  • Canada
  • October 28 2013

Pfizer appealed a decision refusing to strike Teva’s Statement of Claim to the Federal Court, but the appeal was dismissed because a de novo review


Order of prohibition granted in respect of one of two asserted patents
  • Borden Ladner Gervais LLP
  • Canada
  • October 28 2013

Two patents were under consideration by the Court in this application brought pursuant to the Patented Medicines (Notice of Compliance) Regulations


Court of Appeal considers comity as it applies to NOC proceedings
  • Borden Ladner Gervais LLP
  • Canada
  • December 4 2012

Apotex v


Court of Appeal upholds decision relating to sildenafil use patent
  • Borden Ladner Gervais LLP
  • Canada
  • January 27 2014

Pfizer Ireland Pharmaceuticals v. Apotex Inc., 2014 FCA 13 Drug: VIAGRA sildenafil In Apotex' action for impeachment of the Pfizer patent


Antibody patent found valid and infringed
  • Borden Ladner Gervais LLP
  • Canada
  • January 27 2014

The Court recently decided a patent infringement case dealing with antibodies. The claims at issue in AbbVie’s patent relate to the use of a human


Allegations as to non-infringement of Form I held to be justified
  • Borden Ladner Gervais LLP
  • Canada
  • January 23 2014

Teva asserted both non-infringement and invalidity in its Notice of Allegation. The Court noted that invalidity of this patent had been before it


Motion for additional rebuttal witnesses in re-opened trial denied
  • Borden Ladner Gervais LLP
  • Canada
  • November 28 2011

The Defendants brought a motion seeking to call rebuttal witnesses in a trial that has been re-opened to allow evidence that may contradict the evidence given at trial